ALLMedicine™ Neuromuscular Diseases Center
Research & Reviews 689 results
https://clinicaltrials.gov/ct2/show/NCT05041387
Aug 5th, 2022 - PROTOCOL SUMMARY Title: Data Collection for Standard Care of Patients in the EMG Section Study Description: This protocol is designed to provide a repository of information for future hypothesis generation. We will be evaluating patients with neur...
https://clinicaltrials.gov/ct2/show/NCT02892890
Jul 29th, 2022 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired neuropathy characterized by an inflammatory multifocal segmental demyelination. Due to the clinical heterogeneity of this condition and the lack of specific marker tha...
https://clinicaltrials.gov/ct2/show/NCT03645031
Jul 26th, 2022 - Most ALS patients survive less than 5 years after diagnosis, and the main cause of death is respiratory failure. The investigators are interested in the therapeutic potential of acute intermittent hypoxia (AIH) for individuals with neuromuscular d...
https://doi.org/10.1016/j.nmd.2022.06.004
Neuromuscular Disorders : NMD; Bouman K, Gubbels M et. al.
Jul 23rd, 2022 - LAMA2-related muscular dystrophy (LAMA2-MD) and SELENON(SEPN1)-related myopathy (SELENON-RM) are rare neuromuscular diseases caused by mutations in the LAMA2 and SELENON (SEPN1) gene, respectively. Systematic reviews on cardiac features in both ne...
https://doi.org/10.1007/s10741-022-10260-8
Heart Failure Reviews; Alexandridis GM, Pagourelias ED et. al.
Jul 21st, 2022 - Neuromuscular diseases (NMDs) include a broad spectrum of disorders that affect motor unit in every possible site, extending from the cell body of peripheral nerves to the muscle. The different lesion sites make this group of inherited disorders d...
Guidelines 1 results
https://doi.org/10.1161/CIR.0000000000000526
Circulation Feingold B, Mahle WT et. al.
Aug 26th, 2017 - For many neuromuscular diseases (NMDs), cardiac disease represents a major cause of morbidity and mortality. The management of cardiac disease in NMDs is made challenging by the broad clinical heterogeneity that exists among many NMDs and by limit...
Drugs 1 results see all →
Clinicaltrials.gov 127 results
https://clinicaltrials.gov/ct2/show/NCT05041387
Aug 5th, 2022 - PROTOCOL SUMMARY Title: Data Collection for Standard Care of Patients in the EMG Section Study Description: This protocol is designed to provide a repository of information for future hypothesis generation. We will be evaluating patients with neur...
https://clinicaltrials.gov/ct2/show/NCT02892890
Jul 29th, 2022 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired neuropathy characterized by an inflammatory multifocal segmental demyelination. Due to the clinical heterogeneity of this condition and the lack of specific marker tha...
https://clinicaltrials.gov/ct2/show/NCT03645031
Jul 26th, 2022 - Most ALS patients survive less than 5 years after diagnosis, and the main cause of death is respiratory failure. The investigators are interested in the therapeutic potential of acute intermittent hypoxia (AIH) for individuals with neuromuscular d...
https://clinicaltrials.gov/ct2/show/NCT04141670
Jul 19th, 2022 - RYR1- related myopathy comprises a group of rare neuromuscular diseases. Affected individuals generally present with delayed motor milestones, muscle weakness, impaired ambulation, and, in severe cases, scoliosis, ophthalmoplegia, and respiratory ...
https://clinicaltrials.gov/ct2/show/NCT05460156
Jul 15th, 2022 - Objectives To explore the feasibility of delivering and evaluating NM Bridges through a single, specialist service: Feasibility of evaluation To examine the acceptability and performance of candidate outcome measures that consider the priorities, ...
News 27 results
https://www.medscape.com/viewarticle/970530
Mar 18th, 2022 - Neurological disorders can be some of the most difficult conditions to diagnose. Symptoms are similar for multiple different conditions and sometimes they vary a lot between patients, which can make diagnosis hard to pinpoint. Delays means that in...
https://www.mdedge.com/chestphysician/article/242654/sleep-medicine/sleep-disordered-breathing-neuromuscular-disease-early
Christine Kilgore, MDedge News
Jul 8th, 2021 - Sleep-disordered breathing is common in patients with neuromuscular disease and is increasingly addressed with noninvasive ventilation, but its patterns go beyond obstructive sleep apnea (OSA) and include hypoventilation, hypoxemia, central sleep.
https://www.onclive.com/view/dalantercept-falls-short-in-phase-ii-rcc-trial
Nov 13th, 2020 - The combination of dalantercept plus axitinib (Inlyta) failed to significantly improve progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to results from the phase II DART trial. ...
https://www.reuters.com/article/us-exonics-therapeutics-m-a-vertex-pharm/vertex-pharmaceuticals-expands-into-duchenne-gene-therapy-with-new-deals-idUSKCN1T72YK
Jun 6th, 2019 - (Reuters) - Vertex Pharmaceuticals Inc said here on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million. Exonics Therapeutics develops gene edi...